Skip to main content

Lineage Cell Therapeutics, Inc. (LCTX) research

Lineage Cell Therapeutics, Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$1.03
As of

Lineage Cell Therapeutics, Inc. (LCTX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.

As of . Source: SEC EDGAR filings for LCTX. Method and limitations.

SHARE THIS CARD

Share the LCTX intelligence card

A branded snapshot of LCTX: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion LCTX intelligence card preview
Post to X
LIVE TERMINAL

See LCTX live in the terminal

Track LCTX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live LCTX terminal, free

Active signals for LCTX

FREE, NO ACCOUNT

Every signal on LCTX, as it fires

You are seeing 5 of 10 signals recorded on LCTX since 2026-05-30.

The five above landed across 2 days. The other 5 were recorded on 1 other days. 6 of the 10 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in LCTX (2026Q2)

Manager / securityMarket value% portfolioQoQ
MILLENNIUM MANAGEMENT LLCCUSIP 53566P109 · 2026Q2$4M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 53566P109 · 2026Q2$1.8M0.00%,
CITADEL ADVISORS LLCCUSIP 53566P109 · 2026Q2$558K0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 53566P109 · 2026Q2$72K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, LCTX

LCTX against its peers

LCTX's operating margin of -251.6% ranks in the 75th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.

MetricLCTXPeer medianPercentilen
Revenue FY14.6M USD7.1M USD5817
Operating margin-251.6%-621.1%7517
Net margin-436.5%-565.5%5317
Return on equity-142.6%-55.2%2918

Peers (23): TRDA, ACIU, CAMP, MGNX, BCYC, LYEL, NWBO, FHTX, PALI, GLSI, ANIK, PRQR, PYXS, RNAC, NAGE, CYDY, ALXO, IMRX, UPB, WHWK, CGEN, ZNTL, YDES. Left out: CUVL (no annual filing), VCRE (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (LCTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more LCTX signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to LCTXand get the insider, 13F, options, and confluence read in one view.

Open the live LCTX terminal, free